Outcomes at 2 and 5 years of the overall study population, and detailed for each ELN 2017 risk category
| . | Overall survival % (SE) . | Event-free survival % (SE) . | Cumulative incidence of relapse % (SE) . | Cumulative incidence of non-relapse mortality % (SE) . | ||||
|---|---|---|---|---|---|---|---|---|
| All patients | 2y 54.2 (1.8) | 2y 41.7 (1.8) | 2y 35.1 (1.9) | 2y 10.8 (1.2) | ||||
| 5y 44.4 (2) | 5y 35.9 (1.9) | 5y 39.1 (2.1) | 5y 13.6 (1.5) | |||||
| ELN 2017 favorable | 2y 77.3 (2.4) | 2y 66.5 (2.7) | 2y 22.7 (2.6) | 2y 3.5 (1.1) | ||||
| 5y 70.3 (3) | 5y 59.6 (3.1) | 5y 27.7 (3) | 5y 6.8 (1.8) | |||||
| ELN 2017 intermediate | 2y 51.8 (5.2) | *** | 2y 36.7 (5) | *** | 2y 36.9 (5.7) | *** | 2y 10.4 (3.5) | *** |
| 5y 45.7 (6.1) | 5y 30.6 (5.9) | 5y 39.5 (6.1) | 5y 14.2 (5.1) | |||||
| ELN 2017 adverse | 2y 32.5 (3.2) | 2y 18 (2.7) | 2y 51.5 (4.1) | 2y 18.5 (3.1) | ||||
| 5y 23.1 (3.2) | 5y 15.4 (2.7) | 5y 52.6 (4.1) | 5y 20.7 (3.4) | |||||
| . | Overall survival % (SE) . | Event-free survival % (SE) . | Cumulative incidence of relapse % (SE) . | Cumulative incidence of non-relapse mortality % (SE) . | ||||
|---|---|---|---|---|---|---|---|---|
| All patients | 2y 54.2 (1.8) | 2y 41.7 (1.8) | 2y 35.1 (1.9) | 2y 10.8 (1.2) | ||||
| 5y 44.4 (2) | 5y 35.9 (1.9) | 5y 39.1 (2.1) | 5y 13.6 (1.5) | |||||
| ELN 2017 favorable | 2y 77.3 (2.4) | 2y 66.5 (2.7) | 2y 22.7 (2.6) | 2y 3.5 (1.1) | ||||
| 5y 70.3 (3) | 5y 59.6 (3.1) | 5y 27.7 (3) | 5y 6.8 (1.8) | |||||
| ELN 2017 intermediate | 2y 51.8 (5.2) | *** | 2y 36.7 (5) | *** | 2y 36.9 (5.7) | *** | 2y 10.4 (3.5) | *** |
| 5y 45.7 (6.1) | 5y 30.6 (5.9) | 5y 39.5 (6.1) | 5y 14.2 (5.1) | |||||
| ELN 2017 adverse | 2y 32.5 (3.2) | 2y 18 (2.7) | 2y 51.5 (4.1) | 2y 18.5 (3.1) | ||||
| 5y 23.1 (3.2) | 5y 15.4 (2.7) | 5y 52.6 (4.1) | 5y 20.7 (3.4) | |||||
P-value < .001; SE, Standard error.